Normunity: Funding, Investors & Team (Oct 2026)
Normunity is a biotechnology company in Boston, Massachusetts and West Haven, Connecticut that is developing a new type of precision immuno-oncology drugs known as immune normalizers. These drugs target unique mechanisms that help the body's natural immune system fight against cancer. The company is collaborating with Dr. Lieping Chen at Yale School of Medicine to identify and target immune disruption in cancer using proprietary discovery platforms. Normunity is working on a pipeline of immune normalizers that address issues such as the exclusion of T-cells from tumors and other barriers to normal immune function in cancer.
Normunity has raised $140M across 2 funding rounds on record, the most recent a Series B of $75.0M announced in Jan 2025.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Normunity Company Profile and Key Stats
Latest funding round on record: Jan 2025.
Normunity Funding Rounds
Normunity raised $65.0M in a Series A announced in Oct 2022.
2.3 years later, a Series B of $75.0M was announced in Jan 2025.
Normunity Founders and Leadership Team
Contact details for the Normunity team: 1 of 1 has an email address on file.
Start 14-day free trial →Normunity Funding Compared to Other Biotechnology Startups
Normunity's latest round of $75.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Normunity in Biotechnology and West Haven
Companies Similar to Normunity
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Datavant is a developer of a healthcare data platform dedicated to assisting in protecting, matching, and…
Normunity Funding FAQs
What does Normunity do?
Normunity is a biotechnology company in Boston, Massachusetts and West Haven, Connecticut that is developing a new type of precision immuno-oncology drugs known as immune normalizers. These drugs target unique mechanisms that help the body's natural immune system fight against cancer. The company is collaborating with Dr. Lieping Chen at Yale School of Medicine to identify and target immune disruption in cancer using proprietary discovery platforms. Normunity is working on a pipeline of immune normalizers that address issues such as the exclusion of T-cells from tumors and other barriers to normal immune function in cancer.
How much funding has Normunity raised?
Normunity has raised $140M across 2 rounds on record. The most recent is a Series B of $75.0M announced in Jan 2025.
When did Normunity last raise funding?
Normunity's most recent funding round on record is a Series B of $75.0M, announced in Jan 2025.
Who founded Normunity?
FundedIQ lists Rachel W Humphrey (Founder) at Normunity.
Where is Normunity headquartered?
Normunity is based in West Haven, Connecticut, United States.
How many employees does Normunity have?
Normunity is in the 11-50 employee band.
How does Normunity's funding compare to other Biotechnology startups?
Normunity's latest round of $75.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Normunity Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Normunity is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.